Prominent publications by Norman Wolmark

KOL Index score: 29416

BACKGROUND: Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or ...

Also Ranks for: Carboplatin Paclitaxel |  neoadjuvant chemotherapy |  3 trial |  negative breast |  parp inhibitor veliparib
KOL Index score: 24688

CONTEXT: Among cancer-free women aged 35 years or older, tamoxifen reduced the incidence of estrogen receptor (ER)-positive but not ER-negative breast cancer. The effect of tamoxifen on breast cancer incidence among women at extremely high risk due to inherited BRCA1 or BRCA2 mutations is unknown.

OBJECTIVE: To evaluate the effect of tamoxifen on incidence of breast cancer among cancer-free women with inherited BRCA1 or BRCA2 mutations.


Also Ranks for: Breast Cancer |  inherited mutations |  women brca1 |  tamoxifen incidence |  prevention trial
KOL Index score: 23524

BACKGROUND: In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine the effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors and no axillary lymph node involvement. The findings indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease. However, questions arose about how long ...

Also Ranks for: Tamoxifen Therapy |  5 years |  breast cancer |  survival disease |  positive tumors
KOL Index score: 22078

BACKGROUND: Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.

METHODS: The double-blind, randomised, phase 3 National Surgical Adjuvant Breast and Bowel Project (NSABP) ...

Also Ranks for: Ductal Carcinoma |  postmenopausal women |  tamoxifen anastrozole |  situ lumpectomy |  phase 3
KOL Index score: 21831

CONTEXT: Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.

OBJECTIVE: To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes.

DESIGN, SETTING, AND PATIENTS: The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, ...

Also Ranks for: Raloxifene Tamoxifen |  invasive breast |  nsabp study |  thromboembolic events |  uterine cancer
KOL Index score: 21799

BACKGROUND: We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients.

METHODS: For this open-label, ...

Also Ranks for: Lapatinib Trastuzumab |  neoadjuvant therapy |  3 trial |  surgery patients |  weekly paclitaxel
KOL Index score: 19600

BACKGROUND: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which ...

Also Ranks for: Pathological Complete Response |  ypt0 ypn0 ypt0 |  pooled analysis |  breast chemotherapy |  surrogate endpoint
KOL Index score: 18640

BACKGROUND: The finding of a decrease in contralateral breast cancer incidence following tamoxifen administration for adjuvant therapy led to the concept that the drug might play a role in breast cancer prevention. To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992.

METHODS: Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age ...

Also Ranks for: Breast Cancer |  bowel project |  risk tamoxifen |  national surgical |  lobular carcinoma situ
KOL Index score: 18182

BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a ...

Also Ranks for: Docetaxel Capecitabine |  addition bevacizumab |  doxorubicin cyclophosphamide |  breast cancer |  diseasefree survival
KOL Index score: 18045

BACKGROUND: The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.

METHODS: The study was done at 333 hospitals in North America. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast ...

Also Ranks for: Ductal Carcinoma |  tamoxifen anastrozole |  5 years |  sexual functioning |  vaginal symptoms
KOL Index score: 18043

In 1985 we presented results of a randomized trial involving 1843 women followed for five years that indicated that segmental breast resection (lumpectomy) followed by breast irradiation is appropriate therapy for patients with Stage I or II breast cancer (tumor size, less than or equal to 4 cm), provided that the margins of the resected specimens are free of tumor. Women with positive axillary nodes received adjuvant chemotherapy. Lumpectomy followed by irradiation resulted in a ...

Also Ranks for: Total Mastectomy |  breast cancer |  lumpectomy irradiation |  adjuvant chemotherapy |  local recurrence tumor
KOL Index score: 17979

PURPOSE: Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.

PATIENTS AND METHODS: National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel plus 52 weeks of trastuzumab beginning concurrently with paclitaxel in patients with ...

Also Ranks for: Cardiac Dysfunction |  adjuvant therapy |  patients trastuzumab |  cyclophosphamide paclitaxel |  monoclonal antibodies
KOL Index score: 17615

BACKGROUND: Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with ...

Also Ranks for: Breast Irradiation |  equivalence trial |  patients apbi |  accelerated partial |  conserving surgery
KOL Index score: 17563

BACKGROUND: Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND). The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether SLN resection in patients with breast cancer achieves the same survival and regional control as ALND, but with fewer side-effects.

METHODS: NSABP B-32 was a randomised controlled phase 3 trial ...

Also Ranks for: Negative Patients |  breast cancer |  regional control |  sln resection |  diseasefree survival
KOL Index score: 17516

BACKGROUND: Tamoxifen reduces the risk for contralateral breast cancer by approximately 30%-50%, with benefits probably limited to women with estrogen receptor (ER)-positive primary disease. In a retrospective analysis of data from National Surgical and Adjuvant Breast and Bowel Project trials B-18, B-22, and B-25, we determined whether the ER status of primary breast cancer predicts the ER status of a subsequent contralateral breast cancer and whether tamoxifen treatment affects this ...

Also Ranks for: Contralateral Breast |  estrogen receptor |  tamoxifen patients |  primary cancer |  hormonal biomarkers

Key People For Breast Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Gabriel * **********
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca * ******
united states colorectal cancer incidence rates
Charles * *****
breast cancer gene expression intrinsic subtypes
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america

Norman Wolmark:Expert Impact

Concepts for whichNorman Wolmarkhas direct influence:Breast cancer,  Adjuvant chemotherapy,  Neoadjuvant chemotherapy,  Colon cancer,  Bowel project,  Neoadjuvant therapy,  Clinical trial,  Radiation therapy.

Norman Wolmark:KOL impact

Concepts related to the work of other authors for whichfor which Norman Wolmark has influence:Breast cancer,  Neoadjuvant chemotherapy,  Lymph node,  Ductal carcinoma,  Radiation therapy,  Estrogen receptor,  Gene expression.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA | NSABP/NRG Oncology, Pittsburgh, PA, USA | NRG Oncology and University of Pittsburgh, Pittsburgh, PA; | UPMC Hillman Cancer Center, Pittsburgh, PA, USA | NSABP/NRG Oncology, and Th